×
About 1,286 results
Bladder Cancer
https://www.cancer.org/cancer/bladder-cancer.html

Jul 28th, 2019 - "Whether you (or a loved one) are worried about developing bladder cancer, have just been diagnosed, are going through treatment, or are trying to stay well after treatment, this detailed guide can help you find the answers you need.

FDA grants orphan drug designation to Imfinzi for small cell lung cancer
https://www.healio.com/hematology-oncology/lung-cancer/news/online/%7B1a3bbdcb-d89d-41b5-ba26-640b5acd5ee1%7D/fda-grants-orphan-drug-designation-to-imfinzi-for-small-cell-lung-cancer

Jul 11th, 2019 - The FDA granted orphan drug designation to durvalumab for the treatment of small cell lung cancer. Durvalumab (Imfinzi, AstraZeneca) — a human monoclonal antibody that binds to PD-L1 — already is approved in the United States for treatment of patients with unresectable, stage III non-small cell lung cancer who underwent chemotherapy and radiation. The agent also is approved for previously tr...

VENTANA PD-L1 (SP142) Assay - P160002/S009
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm633972.htm

Mar 10th, 2019 - What is it? It is a test done in a laboratory using samples from triple negative breast cancer patients which doctors use to see if patients have programmed cell death ligand (PD-L1) in their cancer. When is it used? To help doctors decide whether atezolizumab is the best treatment choice for their patients. Atezolizumab is a drug that blocks PD-L1. Doctors use atezolizumab in combination wi...

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).
https://meetinglibrary.asco.org/record/170185/abstract

Feb 14th, 2019 - The PD-1 inhibitor pembro has durable antitumor activity in pts with metastatic urothelial carcinoma. Upregulation of the PD-1 pathway has been observed in BCG-resistant NMIBC, suggesting pembro may benefit. Efficacy and safety of pembro in pts with HR, BCG-unresponsive NMIBC was evaluated in the single-arm phase 2 KEYNOTE-057 study; updated results for pts with carcinoma in situ (CIS) with or ...

A Retrospective Study of Patients Undergoing Radical Cystectomy and Receiving Peri-Operative Naloxegol or Alvimopan: Comparison of Length of Stay
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298757/

Oct 11th, 2018 - Alvimopan is a μ-opioid receptor antagonist used in the post-operative period to decrease rates of post-operative ileus (POI) following radical cystectomy (RC) and thereby shorten length of stay (LOS). Naloxegol is a much less expensive drug of the same class that has yet to be studied for prevention of POI in the peri-operative period. The purpose of the current study is to evaluate the differ...

Updated durvalumab monotherapy data confirm results in urothelial bladder cancer
https://www.astrazeneca.com/media-centre/press-releases/2017/updated-durvalumab-monotherapy-data-confirm-results-in-urothelial-bladder-cancer-17022017.html

Feb 16th, 2017 - AstraZeneca and its global biologics research and development arm, MedImmune, today announced updated efficacy and safety data for durvalumab in patients with locally-advanced or metastatic urothelial cancer (UC). Updated results from the Phase I/II trial, presented at the 2017 ASCO Genitourinary Cancers Symposium, showed an objective response rate (ORR) of 20.4% in all evaluable patients (n...

Circumcision Policy Statement
https://pediatrics.aappublications.org/content/130/3/585
Pediatrics

Aug 30th, 2012 - Male circumcision is a common procedure, generally performed during the newborn period in the United States. In 2007, the American Academy of Pediatrics (AAP) formed a multidisciplinary task force of AAP members and other stakeholders to evaluate the recent evidence on male circumcision and update the Academy’s 1999 recommendations in this area. Evaluation of current evidence indicates that the...

Oncologists Respond Rapidly to Labeling Changes for Immunotherapy
https://www.medscape.com/viewarticle/920312

Oct 22nd, 2019 - Oncologists appear willing to change clinical practice quickly in response to safety announcements, a new study suggests. A few years ago, the US Food and Drug Administration (FDA) changed its labeling on first-line immunotherapy for bladder cancer. The study found that use of these therapies among oncologists dropped by about 50% within 6 months of the revised labeling. The findings were publi...

Federal Health Care Cancer Data Trends 2019
https://www.mdedge.com/fedprac/article/209596/federal-health-care-cancer-data-trends-2019?channel=27011

Oct 7th, 2019 - Click here to access Federal Health Care Cancer Data Trends 2019 Table of Contents Introduction Cancer in the VA: The Big Picture Hepatocellular Carcinoma Prostate Cancer Multiple Myeloma Lung Cancer in the VA at a National Level Lung Cancer – Regional Snapshot: Kansas City VA Colorectal Cancer Leukemias Lymphomas Renal Cell Carcinoma Bladder Cancer Afterword.

UK Guidelines Offer Coherent Approach to Rare Bladder Cancer
https://www.medscape.com/viewarticle/918881

Oct 6th, 2019 - BARCELONA — A standardised approach to the diagnosis of a rare and aggressive form of bladder cancer has been developed by UK experts after conducting, for the first time, a national audit that gave a picture of the typical patient presentation and outcomes with current treatment approaches. Small cell bladder cancer (SCBC) accounts for less than 1% of all carcinomas of the bladder and is assoc...

Immunotherapy Added to CT Might Just Work in Bladder Cancer
https://www.medscape.com/viewarticle/919192

Sep 29th, 2019 - Dr Enrique Grande BARCELONA, Spain — Immunotherapy added to chemotherapy might just work in advanced bladder cancer: results so far from IMvigor130 show an improvement in progression-free survival (PFS), but the data for overall survival (OS) are immature. Immunotherapy with atezolizumab (Tecentriq, Roche/Genentech) in combination with chemotherapy (CT) achieved a statistically longer median PF...

Bladder Cancer Federal Health Care Data Trends
https://www.mdedge.com/fedprac/avaho/article/208862/colon-and-rectal/bladder-cancer-federal-health-care-data-trends?channel=263
Julie N. Graff, MD

Sep 26th, 2019 - (function(n){var r="_ion_ionizer",t=n. getElementsByTagName("script"),i;t=t[t.

Warning Stalled Immunotherapy Takeover in Bladder Cancer
https://www.medpagetoday.com/hematologyoncology/othercancers/82355

Sep 24th, 2019 - The FDA's May 2018 warning against prescribing immunotherapy alone in bladder cancer patients with low PD-L1 expression quickly reversed the surge in use of these agents as first-line therapy, according to a new analysis. In unadjusted numbers, immune checkpoint inhibitor use in first-line decreased from 51.9% prior to the agency's warning to 30.3% half a year later, while rates of platinum-bas...

In Bladder Cancer, New Systemic Treatments Arise
https://www.mdedge.com/fedprac/avaho/article/208575/colon-and-rectal/bladder-cancer-new-systemic-treatments-arise/page/0/1?channel=337

Sep 23rd, 2019 - Moving forward, she said, “continued research is needed to learn how to incorporate predictive molecular profiles to optimize treatment selection. ” Dr.

Alternatives for Bladder Cancer Tx During Ongoing BCG Shortage
https://www.medscape.com/viewarticle/917829

Sep 5th, 2019 - The ongoing shortage of bacillus Calmette-Guérin (BCG), used intravesically to treat early-stage bladder cancer, continues to motivate experts to identify alternatives for the treatment of nonmuscle invasive bladder cancer (NMIBC). There has been a worldwide intermittent shortage of BCG for some years. The problem is compounded in low- and middle-income countries, where costs can make alternati...

Tandem transplants provide EFS edge in pediatric neuroblastoma
https://www.mdedge.com/neurology/article/207309/cns/brain-cancer/tandem-transplants-provide-efs-edge-pediatric?channel=27970
Neil Osterweil

Aug 29th, 2019 - For young patients with high-risk neuroblastoma, an intensive consolidation regimen with tandem autologous stem cell transplants was associated with significantly better event-free survival, compared with single-transplant consolidation, results of a randomized trial show. Among 355 patients with high-risk neuroblastoma, the 3-year event-free survival (EFS) rate was 61.

Tandem Autologous Stem-Cell Transplant Boosts Event-Free Neuroblastoma Survival
https://www.medscape.com/viewarticle/917376

Aug 28th, 2019 - NEW YORK (Reuters Health) - Tandem autologous stem-cell transplant (ASCT) may provide better event-free survival (EFS) in patients with high-risk neuroblastoma, compared with single ASCT, a new clinical trial shows. "Although it was our hypothesis that tandem transplant would decrease risk for recurrence, we were surprised by the positive results, including the magnitude of the difference, and ...

Practice-Changing Trial in Neuroblastoma, but Questions Remain
https://www.medpagetoday.com/hematologyoncology/othercancers/81826

Aug 27th, 2019 - Children with newly diagnosed high-risk neuroblastoma who received tandem autologous stem-cell transplant as consolidation therapy had longer event-free survival (EFS) than those who received single stem-cell transplant, a randomized Children's Oncology Group study showed. At 3 years, the EFS rate was 61.6% among patients who received tandem transplant and 48.4% for those who received single tr...

U.S. FDA Proposes New Health Warnings on Cigarette Packs, Advertisements
https://www.medscape.com/viewarticle/916899

Aug 16th, 2019 - (Reuters) - The U.S. Food and Drug Administration on Thursday proposed new health warnings for cigarette packages and advertisements, as small size and lack of an image in current warnings make them virtually invisible. Cigarette packages would have to carry colored photos about half their size and outline lesser known health risks such as bladder cancer, diabetes, erectile dysfunction and cond...